Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction

Patients receiving therapy for the secondary prevention of myocardial infarction (MI) are still at high risk of a major cardiovascular event or death despite the use of currently available treatment strategy. Vorapaxar, an oral protease-activated receptor antagonist, is a novel antiplatelet drug tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Kehinde, Obamiro, Kunle, Rotimi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832913/
https://www.ncbi.nlm.nih.gov/pubmed/27134460
http://dx.doi.org/10.4103/0975-7406.171690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832913/
https://www.ncbi.nlm.nih.gov/pubmed/27134460
http://dx.doi.org/10.4103/0975-7406.171690

Ejemplares similares